Aurélie Lagrange

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 232 citations

Medicine, Oncology, Chemotherapy +14

MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells

Emeric Limagne, Lisa Nuttin, Marion Thibaudin et al. · Cancer Cell · 2022 · 217 citations

Medicine, Cancer Biology, Oncology +14

Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients

Emeric Limagne, Corentin Richard, Marion Thibaudin et al. · OncoImmunology · 2019 · 205 citations · Full text

Medicine, Immunology, Oncology +17

Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy

Jean-David Fumet, Corentin Richard, Fanny Ledys et al. · British Journal of Cancer · 2018 · 174 citations · Full text

Medicine, Immunology, Oncology +17

Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i> –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

James Chih‐Hsin Yang, Dae Ho Lee, Jong‐Seok Lee et al. · Journal of Clinical Oncology · 2024 · 142 citations · Full text

Medicine, Oncology, Pharmacology +14